/

Sociétés

No

Non vérifié

Novo Nordisk

Ce que nous écrivons

Actu PeopleChronique SociétéFitness/Bien-êtreMédecine - DiversSanté

5 communiqués de presse

Voir tous les communiqués de presse

11/07/2026

Santé

Fitness/Bien-être

Actu People

Chronique Société

Médecine - Divers

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Source

Émetteur

1.00

0

Press Release cover image

26/06/2026

Santé

Fitness/Bien-être

Actu People

Chronique Société

Médecine - Divers

Écologie/Santé environnementale

Agriculture

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

Source

Émetteur

1.00

0

Press Release cover image

06/06/2026

Actu People

Chronique Société

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

Source

Émetteur

1.00

0

Press Release cover image

29/04/2026

Santé

Fitness/Bien-être

Médecine - Divers

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Source

Émetteur

1.00

0

Press Release cover image

01/04/2026

Santé

Fitness/Bien-être

Médecine - Divers

Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2)[1]

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0